452 related articles for article (PubMed ID: 22465368)
1. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
Yamashiro K; Tomita K; Tsujikawa A; Nakata I; Akagi-Kurashige Y; Miyake M; Ooto S; Tamura H; Yoshimura N
Am J Ophthalmol; 2012 Jul; 154(1):125-36. PubMed ID: 22465368
[TBL] [Abstract][Full Text] [Related]
2. Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Hata M; Tsujikawa A; Miyake M; Yamashiro K; Ooto S; Oishi A; Nakanishi H; Takahashi A; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):221-7. PubMed ID: 24961698
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study.
Kuroda Y; Yamashiro K; Miyake M; Yoshikawa M; Nakanishi H; Oishi A; Tamura H; Ooto S; Tsujikawa A; Yoshimura N
Ophthalmology; 2015 Nov; 122(11):2303-10. PubMed ID: 26271842
[TBL] [Abstract][Full Text] [Related]
4. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
[TBL] [Abstract][Full Text] [Related]
5. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Kawashima Y; Oishi A; Tsujikawa A; Yamashiro K; Miyake M; Ueda-Arakawa N; Yoshikawa M; Takahashi A; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2015 Sep; 253(9):1471-7. PubMed ID: 25391986
[TBL] [Abstract][Full Text] [Related]
6. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.
Matsumiya W; Honda S; Kusuhara S; Tsukahara Y; Negi A
BMC Ophthalmol; 2013 Apr; 13():10. PubMed ID: 23557322
[TBL] [Abstract][Full Text] [Related]
8. Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment.
Kuroda Y; Yamashiro K; Tsujikawa A; Ooto S; Tamura H; Oishi A; Nakanishi H; Miyake M; Yoshikawa M; Yoshimura N
Am J Ophthalmol; 2016 Jan; 161():94-103.e1. PubMed ID: 26432927
[TBL] [Abstract][Full Text] [Related]
9. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
Sakurada Y; Nakamura Y; Yoneyama S; Mabuchi F; Gotoh T; Tateno Y; Sugiyama A; Kubota T; Iijima H
Ophthalmic Res; 2015; 53(1):2-7. PubMed ID: 25472810
[TBL] [Abstract][Full Text] [Related]
10. Differentiating Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy Using OCT B-Scan.
Kokame GT; Omizo JN; Kokame KA; Yamane ML
Ophthalmol Retina; 2021 Oct; 5(10):954-961. PubMed ID: 34022443
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
13. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
[TBL] [Abstract][Full Text] [Related]
14. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up.
Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
Ophthalmologica; 2015; 234(1):33-9. PubMed ID: 26112059
[TBL] [Abstract][Full Text] [Related]
17. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.
Hikichi T; Higuchi M; Matsushita T; Kosaka S; Matsushita R; Takami K; Ohtsuka H; Ariga H
Am J Ophthalmol; 2012 Jul; 154(1):117-124.e1. PubMed ID: 22465366
[TBL] [Abstract][Full Text] [Related]
18. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
Calvo-Gonzalez C; Reche-Frutos J; Fernández-Vigo JI; Donate-López J; Serrano-García I; Fernández-Pérez C
Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
[TBL] [Abstract][Full Text] [Related]
20. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy.
Jirarattanasopa P; Ooto S; Nakata I; Tsujikawa A; Yamashiro K; Oishi A; Yoshimura N
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3663-72. PubMed ID: 22570352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
